Dr. Ashok Seth

Chairman

44 Years of Experience

Interventional Cardiologist

MBBS, MRCP, FRCP, FACC, D.Sc

Reg. No.:6648, Delhi Medical Council

Fortis Escorts Heart Institute, New Delhi

English

Consultation Fee ₹ 5000

WhatsApp Us

About Dr. Ashok Seth

Dr. Ashok Seth is a prominent Interventional Cardiologist with over 44 years of experience.
His expertise includes/TAVR Procedure, Cardiac Ablation, Cardiac Catheterization, Carotid Angioplasty And Stenting, Coronary Angiogram, Coronary Angioplasty/Bypass Surgery, Computed Tomography Angiography (CTA), Mitral Heart Valve Repair/Replacement, etc.
After completing his MBBS from Jawahar Lal Nehru University, Aligarh, he also achieved an MD from SGPGI, Lucknow.
Dr. Seth has been honored with Doctorates from six prestigious national universities: AMU, Jamia Millia Islamia, Shiv Nadar, Amity, and Teerthankar Mahavir University.
He was conferred Adjunct Cardiology Professorship at J N Medical College, AMU, and the National Board of Examinations.
He is the founder and course director of five major national and international angioplasty teaching courses: India Valves, India Live, CHIP-CTO India, AICT-Asia PCR, and the Imaging and Physiology Council of India.
He is also the Associate Director of TCT Scientific Sessions (USA) and a Program Committee Member of Euro PCR.
He has been featured in the Limca Book of Records for performing one of the world's highest numbers of angioplasties and angiographies.
Dr. Seth has contributed extensively to this field's development, scientific progress, and education, pioneering numerous angioplasty techniques for India and the Asia Pacific.
Dr. Seth has been invited to speak at more than 450 national and international conferences. He has also taught complex angioplasty techniques through live demonstrations at over 100 national and international meetings worldwide, including prestigious events such as TCT (Transcatheter Cardiovascular Therapeutics) in the USA, Euro PCR in Paris, and Singapore Live in Singapore.
He has over 350 publications to his credit in peer-reviewed Indian and International medical journals, has chapters in 30 books on Cardiology, and has been the Editor of 3 books.
He is an acclaimed teacher and has trained more than 500 cardiologists in India and abroad in advanced angioplasty techniques.

Book Your Appointment With Dr. Ashok Seth

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Query

Education

MBBS, Aligarh Muslim University, Aligarh, 1980
MRCP Royal Colleges Of Physicians and Surgeons, Ireland, 1986
Fellow of the Royal College of Physicians of Canada (FRCP), Canada, 1995
Fellow of the American College of Cardiology (FACC), 1995
Doctor of Science (DSc.), Banaras Hindu University, 1998

Past Experience

Professor (Cardiology), Padmashree Dr. D Y Patil University, 2008
Chief (Interventional Cardiology), Max Heart and Vascular Institute, New Delhi, 2008
Chief (Interventional and Invasive Cardiology), Escorts Heart Institute New Delhi, 2004
Professor (Cardiology), Gandhi Medical College, 2001
Consultant (Cardiology), Queen Elizabeth Hospital, Birmingham, 1988

Awards

IMA Distinguished Interventional Cardiologist Award
B C Roy Award in 2017
Padma Bhushan in 2015
Padma Shri in 2003
Doc N Doc-Gammex Saviour Award in 2014
DMA Centenary Award in 2014
Hero Lifetime Achievement Award in 2014
Vishisht Chikitsa Ratan in 2012
Order of Isabella the Catholic in 2010
Mason Sones Award from the Society of Cardiovascular Angiography Interventions in 2010
Delhi Ratna Award in 2000

Associations/Membership

Cardiological Society of India (CSI)

Paper Published

Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian experience (The OCTACOR India Study), 2024
Última generación de prótesis percutáneas expandibles con balón y autoexpandibles en la estenosis aórtica bicúspide: estudio TRITON,2023
Angiographic quantification of aortic regurgitation following removal octacor implantation; independent core lab adjudication, 2023
One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis-A Multicentre Real-World Experience, 2023
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valve failure: 1-year follow-up from a multicenter experience, 2023
Prosthetic valve thrombosis secondary to heparin-induced thrombocytopenia - Double trouble, 2022
Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex, high-risk PCI in India using a standardized algorithm, 2022
Transcatheter Aortic Valve Implantation for Severe Bicuspid Aortic Stenosis - 2 Years Follow-up Experience From India, 2022
Journal Pre-proof Impact of the 2017 ACC/AHA Guidelines on the Prevalence of Hypertension Among Indian Adults: Results from a Cross-Sectional Survey, 2020
Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The First-in-human MyVal-1 Study, 2020
First-in-Human Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The MyVal-1 Study, 2019
Prevalence of Hypertension among Indian Adults: Results from the Great India Blood Pressure Survey, 2019
Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial, 2019
Chronic total occlusion or non? Chronic total occlusion percutaneous coronary intervention: Do myocytes care, 2019
TCT-64 Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial, 2018
Long-term follow-up of BVS from a prospective multicenter registry: Impact of a dedicated implantation technique on clinical outcomes, 2018
TCTAP A-052 Long-term Outcomes and Technical Challenges of Treating Diffuse Coronary Artery Disease with Everolimus eluting Bioresorbable Vascular Scaffolds, 2018
1968Quantitative angiographic analysis in patients with de novo native coronary artery lesions treated with novel poly-l-lactide based sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 Trial, 2017
First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial, 2017
TCTAP A-003 First-in-human Evaluation of a Novel Poly-L-lactide Based Sirolimus-eluting Bioresorbable Vascular Scaffold for the Treatment of De Novo Native Coronary Artery Lesions: MeRes-1 Trial, 2017
TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial, 2017
CRT-700.04 Three-year Clinical Outcomes Of Biomime Sirolimus-eluting Coronary Stent System With A Biodegradable Polymer In Coronary Artery Disease Patients: A Long-term Follow-up Of The meriT-2 Study, 2017
CRT-700.01 Favourable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System in Treating de novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial, 2017
TCT-434 Implantation of Absorb Bioresorbable Vascular Scaffolds in Small Vessel Coronary Artery Disease: Long-term follow-up, 2016
TCTAP A-004 Rotational Atherectomy and Stenting of Severely Calcified Coronary Arteries with Absorb Bioresorbable Vascular Scaffolds: Analysis of Outcomes, 2016
TCTAP A-054 Long-term Outcome Analysis of Stenting of Diffuse Coronary Lesions with Absorb Bioresorbable Vascular Scaffolds, 2016
Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial, 2016
Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial, 2016
Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial, 2016
Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial, 2015
Salvage of Side Branch by Provisional "TAP Technique" Using Absorb (TM) Bioresorbable Vascular Scaffolds for Bifurcation Lesions: First Case Reports with Technical Considerations, 2014
Use of 'Guidelines' catheter to overcome the failure of delivery of Absorb™ Bioresorbable Vascular Scaffold in calcified tortuous coronary lesions: Technical considerations in 'Real World Patients,' 2014
One-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis of the ABSORB and the SPIRIT Trials, 2014
TCT-212 Efficacy of the Novel BioMime Sirolimus-Eluting Stents with a Biodegradable Polymer in the Treatment of De Novo Coronary Lesions: An Angiographic Subanalysis of the Combined meriT-1 and meriT-2 Prospective Clinical Trials, 2013
TCT-36 One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSORB EXTEND Trials., 2013
The Paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: An angiographic follow-up study, 2013
TCT-649 Safety and Efficacy of Overlapping Second Generation Drug-Eluting Stents Based Upon 2-year Clinical Outcomes. Results from the Pooled Analysis of Five Trials from the International Global RESOLUTE Program. Impact of the New BioMime™ Sirolimus-Eluting Stent in Complex Patients of Daily Practice – Preliminary Results of the MeriT-2 Study, 2012
TCT-649 Safety and Efficacy of Overlapping Second Generation Drug-Eluting Stents Based Upon 2-year Clinical Outcomes. Results from the Pooled Analysis of Five Trials from the International Global RESOLUTE Program. Impact of the New BioMime™ Sirolimus-Eluting Stent in Complex Patients of Daily Practice – Preliminary Results of the MeriT-2 Study, 2012
TCT-649 Safety and Efficacy of Overlapping Second Generation Drug-Eluting Stents Based Upon 2-year Clinical Outcomes. Results from the Pooled Analysis of Five Trials from the International Global RESOLUTE Program. Impact of the New BioMime™ Sirolimus-Eluting Stent in Complex Patients of Daily Practice – Preliminary Results of the MeriT-2 Study, 2012
Efficacy of Everolimus-Eluting Stent Implantation in Patients With Calcified Coronary Culprit Lesions: Two-Year Angiographic and Three-Year Clinical Results From the SPIRIT II Study, 2010
A pooled gender-based analysis comparing the XIENCE V (R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis, 2010
Mammary coronary artery anastomosis without cardiopulmonary bypass through mini-thoracotomy: one-year clinical experience 1 Presented at the 1st World Congress on Minimally Invasive Cardiac Surgery, Paris, May 30–31, 1997. 1, 1998
Percutaneous intra-aortic balloon pulsation for management of life-threatening emergencies in an intensive coronary care unit, 1993